ConvaTec Group PLC
LSE:CTEC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (2.3), the stock would be worth GBX228.78 (9% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.1 | GBX210 |
0%
|
| 3-Year Average | 2.3 | GBX228.78 |
+9%
|
| 5-Year Average | 2.2 | GBX218.46 |
+4%
|
| Industry Average | 0 | GBX0.41 |
-100%
|
| Country Average | 0 | GBX0.3 |
-100%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 2.1 | 31.1 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 13.7 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 1.3 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 2.4 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.8B USD | 2.3 | 31.1 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD | 0.8 | -16 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 5 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 1.9 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | 9.6 | -36.5 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.5B USD | 3.2 | 23.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 141.2 |
Other Multiples
ConvaTec Group PLC
Glance View
ConvaTec Group PLC is a notable player in the realm of medical products and technologies, deftly weaving its narrative within the healthcare industry. Founded in 1978, the company has steadily established itself through strategic expansion and innovation, focusing on improving the lives of patients and enhancing healthcare delivery. The company's core business revolves around four main product categories: Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Each of these sectors is backed by a robust commitment to research and development, allowing ConvaTec to deliver specialized products that cater to both specific patient needs and broader healthcare system demands. ConvaTec's financial model centers around providing essential, high-quality medical solutions that ultimately support improved patient outcomes. The company garners revenue by partnering with hospitals, healthcare providers, and direct consumer channels, ensuring its products reach where they are most needed. With a global footprint spanning multiple continents, ConvaTec not only distributes its products widely but also adapts its strategy to meet the nuanced requirements of diverse markets. By aligning itself closely with caregivers and leveraging cutting-edge technology, the company maintains a sustainable economic engine through both recurring sales from consumables and long-term relationships with its institutional clients.
